Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

• Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billion
• Expands Siemens' market-leading position in industrial software by extending AI-powered Product Lifecycle Management (PLM) portfolio into Life Sciences to seamlessly connect R&D through manufacturing
• Increases Siemens' industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
• Acquisition is another milestone of Siemens' ONE Tech Company program expanding the Siemens Xcelerator platform into Life Sciences software with stronger customers focus, faster innovations and higher growth

MUNICH, April 2, 2025 /PRNewswire/ -- Siemens AG announces that it has signed an agreement to acquire Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for $5.1 billion from Insight Partners. This acquisition represents a strategic milestone for Siemens, expanding its comprehensive Digital Twin technology and AI-powered software into this rapidly growing complementary market. The US company offers a market leading platform with a highly profitable portfolio of scientific applications and multi-modal data management for Life Sciences R&D. The company's offering accelerates customers' innovation, delivering next generation collaboration and contextualized data to enable AI-powered multi-modal drug development.

"By acquiring Dotmatics, we're strategically strengthening our position in Life Sciences and creating a world-leading AI-powered PLM software portfolio as part of Siemens Xcelerator. Artificial Intelligence has emerged as a transformative force across various industries, and its application in Life Sciences is becoming increasingly important," said Roland Busch, President and CEO of Siemens AG. "The Dotmatics acquisition is part of our ONE Tech Company growth program, enhancing our leading position in industrial software and helping our customers to innovate even faster."

"The acquisition of Dotmatics drives strong revenue synergies and is highly profitable and cash generative. Financing will be provided primarily through the sale of shares in listed companies, including Siemens Healthineers," said Ralf P. Thomas, CFO of Siemens AG.  

"Following an exciting journey with Insight Partners, where Dotmatics achieved remarkable growth and portfolio expansion, we are thrilled to announce our new chapter with Siemens," said Thomas Swalla, CEO of Dotmatics. "Combining our next-generation scientific intelligence platform and industry-leading scientific applications together with Siemens' Digital Twin and AI capabilities, we'll drive a new wave of innovation in life sciences R&D. Together, we'll accelerate innovation cycles for our customers and help scientists make breakthrough discoveries faster than ever before shaping the future of scientific innovation."

Life Sciences presents an attractive complementary software market opportunity and expands Siemens' industrial software total addressable market by $11 billion. This market is driven by structural shifts, such as increased medication need driven by aging societies and improved access to medicine, new treatment options from advancing science and the necessity for increased collaboration and visibility across complex value chains. These trends underscore the need for digital transformation, with software spending expected to double over the next five years.  

Siemens' expansion within Life Sciences aligns with its strategic goal to accelerate customer innovation across the top industries with the highest R&D spend. The acquisition is part of the investment track of Siemens' ONE Tech Company program and following last week's closing of Altair's acquisition, yet another milestone. This growth program enables Siemens to further expand its market position and reach the next level of performance and value creation. Through acquisitions like this, as well as R&D investments into areas including software, AI-enabled products, connected hardware and sustainability, Siemens is clearly prioritizing capital allocation to strategic growth fields. The acquisition of Dotmatics enables Siemens to scale its technologies into Life Sciences and to fully address growth opportunities in this market. It will allow Siemens to combine its comprehensive manufacturing expertise, industrial simulation and AI capabilities with Dotmatics' leading complementary applications, creating a first-of-its-kind end-to-end digital thread that connects data from research through to production in Life Sciences.

Significant synergies 
Dotmatics is expected to generate more than $300 million revenue in fiscal year 2025 and is highly profitable and cash generative with an adjusted EBITDA margin of above 40 percent. The company's mid-teens revenue growth and high profitability will be immediately accretive to Siemens' growth, EBITDA margins and free cash flow, prior to any synergies. Siemens expects substantial revenue synergies: Medium-term revenue synergies expected of around $100 million per year accelerating to over $500 million per year in the long-term.

Capital structure at closing is expected to be within Siemens' target corridor. Closing of the transaction is anticipated for the first half of fiscal year 2026 subject to customary closing conditions and applicable regulatory approvals.

About Dotmatics 
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and applications, including GraphPad Prism, SnapGene and Geneious, drive efficiency and accelerate innovation. More than 2 million scientists and over 14,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 people dedicated to supporting its customers in over 180 countries. The company is headquartered in Boston, with 14 offices and R&D teams located around the world.

This press release is available at: https://sie.ag/Cu3EN

Follow us at: www.x.com/siemens_press

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company's purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Notes and forward-looking statements
This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in prospectuses, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens' management, of which many are beyond Siemens' control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Report on expected developments and associated material opportunities and risks in the Combined Management Report of the Siemens Report (siemens.com/siemensreport), and in the Interim Group Management Report of the Half-year Financial Report (provided that it is already available for the current reporting year), which should be read in conjunction with the Combined Management Report. Should one or more of these risks or uncertainties materialize, should decisions, assessments or requirements of regulatory authorities deviate from our expectations, should events of force majeure, such as pandemics, unrest or acts of war, occur or should underlying expectations including future events occur at a later date or not at all or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures should not be viewed in isolation or as alternatives to measures of Siemens' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its Consolidated Financial Statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Reference number: HQCOPR202504027147EN

SOURCE Siemens